Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study

• Published in: Discover. Oncology 2023-06, Vol.14 (1), p.105-105, Article 105
• Main Authors: Li, Qi-mei, Sun, Qing-can, Jian, Yan, He, Jing-zhe, Zhu, Hong-bo, Hong, Chang, Zeng, Lin, Li, Rui-ning, Wang, Jia-ren, Li, Yan, Chen, Li-ya, Weng, Xie, Liu, Li, Dong, Han-zhi, Xiao, Lu-shan, Cui, Hao
• Format: Article
• Language: English
• Subjects: Anti-angiogenesis drug; Blood clots; Cancer Research; Clinical trials; Combination therapy; Immune checkpoint inhibitors; Internal Medicine; Kinases; Liver cancer; Lymphatic system; Magnetic resonance imaging; Medical prognosis; Medicine; Medicine & Public Health; Metastasis; Molecular Medicine; Monoclonal antibodies; Oncology; Patients; Primary liver cancer; Radiotherapy; Regulatory approval; Surgical Oncology; Survival analysis; Tumors
• ISSN: 2730-6011; 2730-6011
• DOI: 10.1007/s12672-023-00708-0

Immune checkpoint inhibitors (ICIs) are safe and efficacious treatments for advanced primary liver cancer (PLC). The efficacy of different ICIs in the treatment of liver cancer remains unclear. The purpose of this study was to explore whether there is a difference in the efficacy and safety of various programmed cell death protein 1 (PD-1) inhibitors in combination with lenvatinib in the treatment of unresectable PLC. Patients with PLC treated with lenvatinib in combination with PD-1 inhibitors (camrelizumab, tislelizumab, sintilimab, or pembrolizumab) between January 2018 and December 2021 were retrospectively enrolled. Tumor response, adverse events, and grades were evaluated. Kaplan–Meier analysis and log-rank test were used to compare the overall survival and progression-free survival of patients treated with different PD-1 inhibitors. Cox regression analysis was used for univariate and multivariate analyses to identify clinical variables related to treatment efficacy. This study included a total of 176 patients who received a combination of lenvatinib and PD-1 inhibitors. Of these, 103 patients received camrelizumab, 44 received tislelizumab, 20 received sintilimab, and 9 received pembrolizumab. There was no significant difference in the pairwise comparison of camrelizumab, tislelizumab, sintilimab, and pembrolizumab using Kaplan–Meier survival analysis. Adverse events occurred in 40 (22.7%) patients (grade ≥ 3, 2.3%). The incidence of grade 3 adverse events among the four PD-1 inhibitor groups was below 5%. Camrelizumab, tislelizumab, sintilimab, and pembrolizumab are viable options for patients with unresectable PLC. These PD-1 inhibitors in combination with lenvatinib showed good safety profiles. The results guide selecting treatment for patients with unresectable PLC.